Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00332553 · ClinicalTrials.gov registry record · Phase 2

Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

A Phase 2 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
150
Enrollment target

NCT00332553: Completed Phase 2 study, sponsored by Eli Lilly and Company.

NCT00332553 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00332553, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target

Study Summary

This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women discontinuing continuous combined hormone replacement therapy (ccHRT) compared to women treated with raloxifene HCl 60 mg alone.

Interventions

  • DRUG Raloxifene
  • DRUG medroxyprogesterone acetate
  • DRUG estrogen
  • DRUG 17 beta estradiol

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2002-02
Est. Completion 2004-05
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT00332553 record still lists

NCT00332553 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).

The record links to 0 conditions, and to 4 interventions - of which Raloxifene is the first listed.

NCT00332553 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00332553 about?

NCT00332553 is a clinical study titled "Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen". This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women discontinuing continuous combined hormone replacement therapy (ccHRT) co...

What is the current status of trial NCT00332553?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2002-02. Estimated completion is 2004-05.

What interventions are being tested in trial NCT00332553?

The interventions under investigation include: Raloxifene (DRUG), medroxyprogesterone acetate (DRUG), estrogen (DRUG), 17 beta estradiol (DRUG).

Who is sponsoring clinical trial NCT00332553?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00332553's enrollment target sits among peer trials

150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00332553, the US trial registry maintained by the National Library of Medicine. NCT00332553 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.